BioCentury
ARTICLE | Product Development

Baricitinib improves on SOC survival benefit in hospitalized COVID patients

April 10, 2021 12:13 AM UTC

Lilly and Incyte believe the latest data for baricitinib underscore how the JAK inhibitor can build upon standard of care’s ability to reduce COVID-related death among hospitalized patients even as the therapy missed the primary endpoint of the Phase III COV-BARRIER study.

Preventing death in hospitalized COVID-19 patients — which hasn’t gone down in frequency over the past six to seven months — is still the “most critical unmet need” in the pandemic, Anabela Cardoso, Eli Lilly and Co. (NYSE:LLY) global brand development lead, immunology, told BioCentury. ...

BCIQ Company Profiles

Eli Lilly and Co.